Developer docs
API playgroundTry for free, no card

Search company profiles

Lucerno Dynamics

Full company profile

uuid0003132

Namestring
Lucerno Dynamics
Legal namestring
Lucerno Dynamics, LLC
Websiteurl
lucerno.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Lucerno Dynamics, LLC is a Cary, North Carolina-based medical device company founded in November 2011 that develops the Lara System, a passive surface-sensor platform used during nuclear medicine procedures to detect radiopharmaceutical extravasations — the inadvertent leakage of injected radioactive tracers into surrounding tissue rather than the intended vein. The Lara System applies topical sensors to the patient's skin to detect radiation during the entire uptake period without emitting energy itself, producing real-time time-activity curves (TACs) that can be stored in PACS as part of the patient record. The companion Ellexa Explorer software scores bolus injections, displays histograms, runs advanced analytics, and generates monthly QA reports; Lara Real-Time Visualization (RTV) extends the platform with second-by-second graphical feedback and statistical control charts for therapeutic radiopharmaceutical administrations. Lucerno has also built a deep learning classifier that labels TAC data to identify extravasated injections.

The company monetizes through hardware sales of the Lara System (sensors, adhesive pads, monitoring equipment) bundled with Ellexa software, sold via direct enterprise field sales to hospital and academic nuclear medicine departments and via channel partners — most notably a Master Reseller Agreement with Siemens Healthineers (signed July 2021) covering US distribution, supplemented by a global partners network spanning Australia, Singapore, Japan, and Europe. Pricing is proposal-based and undisclosed, with multi-year contracts typical of medical imaging capital purchases. Key accounts include Carilion Clinic, Mayo Clinic, Saint Louis University, Wake Forest Baptist Hospital, and University of Pennsylvania, with the technology clinically validated across nearly 50,000 administrations.

The company's strategic posture has combined clinical evidence generation (the multi-center Lara-QI study), regulatory advocacy (a successful 2022 NRC petition for rulemaking to close the extravasation reporting exemption), and channel-led commercialization. After raising $6.34M in Series A equity in 2016 and several smaller debt and equity tranches through 2023, the company remained sub-scale at 1–10 employees, and in July 2026 sold its core Lara and Ellexa assets to Radnostix, Inc., signaling a transition out of independent operations.

Short descriptiontext

Lucerno Dynamics is a Cary, NC medical device company that developed the Lara System, passive skin sensors with companion Ellexa software that detect radiopharmaceutical extravasations in real time during nuclear medicine procedures for hospital and academic imaging departments.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCary, United States
HQ citystring
Cary
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
radiopharmaceutical extravasation monitoring, nuclear medicine injection quality, medical radiation sensors, PET/CT quality assurance, radiotherapy administration monitoring
Industry3 codes
PRIMARYHLAHABAI
Imaging Informatics & Workflow (PACS/RIS/VNA)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLACALAL
Quality, Peer Review & Compliance Tools (MQSA/ACR/QA)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACALAK
Teleradiology Platforms & Reading Workflow
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
NAICS code1 code
  • Analytical Laboratory Instrument Manufacturing334516
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Nuclear Medicine Medical Devices
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Device Sales - Lara System
TypeHardware Sales
Description

Sale of the Lara System hardware including sensors, adhesive pads, and associated monitoring equipment for nuclear medicine facilities.

lucerno.com
2Software - Ellexa Explorer
TypeOthers
Description

PC application software for data analysis, quality assurance reporting, and advanced analytics. Provided as part of the Lara System offering.

lucerno.com
3Therapy Response Monitoring (Investigational)
TypeHardware Sales
Description

Investigational technology for therapy response monitoring in solid tumor treatment, used under investigational device exemption. Not yet cleared or approved by FDA for this indication.

lucerno.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Lara System for nuclear medicine injection monitoring
ModelOtherBilling cadenceMulti-year contract
Notes

No publicly listed pricing. Company uses contact/sales process: Contact now → Receive proposal in days → Start monitoring within weeks.

lucerno.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1LARA System
Description

FDA-listed system that dynamically measures the presence of radiopharmaceutical in an organ or body region during uptake period; provides quality control, dosimetry, and quality assurance for nuclear medicine administrations

lucerno.com
+2 more records
Core offering1 text field

Lucerno Dynamics develops and sells the Lara System, a medical device platform that uses topical surface sensors to dynamically detect and measure radiopharmaceutical extravasations during nuclear medicine procedures. The system provides real-time quality control data, time-activity curve analysis, and quality assurance software (Ellexa Explorer) for hospital nuclear medicine departments performing PET/CT scans and therapeutic radiopharmaceutical administrations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Extravasation rates reduced to 2-16% when centers implement quality improvement programs with Lara System
+3 more records
Product overview1 text field

Lucerno Dynamics offers a unified product ecosystem centered on the Lara System platform for detecting and monitoring radiopharmaceutical extravasations during nuclear medicine procedures. The core Lara System uses passive surface sensors to provide real-time quality control data. Key software modules include Ellexa Explorer (for data analysis, automated scoring, and reporting) and Lara Real-Time Visualization (for therapeutic monitoring with statistical control charts). These components work together to help clinicians identify injection errors within seconds, evaluate their impact through time-activity curves, and reduce extravasation frequency through quality assurance programs.

Product and service3 records
1Lara System
CategoryMedical Device / Radiopharmaceutical Monitoring
Description

The Lara System is the primary product platform using passive surface sensors applied to a patient's skin to detect radiation emitted from areas of interest during and after radiopharmaceutical administration. It provides real-time quality control data for detecting extravasations in nuclear medicine procedures such as PET/CT scans and radiotherapeutic administrations. Targeted at hospital nuclear medicine departments, cancer centers, and imaging facilities.

2Lara Real-Time Visualization (RTV)
CategoryMedical Device Software / Radiotherapy Monitoring
Description

Lara RTV provides second-by-second graphical time-activity curve feedback on a computer monitor during therapeutic radiopharmaceutical administrations. Includes statistical control charts that alert technologists when administrations may have been extravasated, enabling early intervention to minimize accidental radiation exposures. Targeted at nuclear medicine technologists performing radiotherapeutic administrations.

3Ellexa Explorer Software
CategoryMedical Software / Quality Assurance
Description

Ellexa Explorer is a PC application that automatically scores bolus injections, displays histograms of injection scores, provides advanced analytics to identify factors leading to injection issues, and generates monthly reports for departments and individual technologists. Targeted at nuclear medicine department quality managers and QA personnel.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Radnostix
Strategic tierCoreTypeOthersAnnounced on2026-07-02
Description

Radnostix acquired key assets from Lucerno Dynamics including the LARA System technology platform, ELLEXA Explorer software, and associated intellectual property for radiopharmaceutical and nuclear medicine applications. Note: This represents an asset acquisition of Lucerno's technology portfolio.

pulse2.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-07-08
Description

Master Resellers Agreement making the Lara System part of Siemens Healthineers' portfolio of medical imaging products. Siemens Healthineers became Lucerno's first United States partner reseller, making Lara System available to nuclear medicine customers nationwide.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Washington, D.C. partners supporting Lucerno's public policy efforts to improve patient safety and nuclear medicine procedure quality through regulatory engagement.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Philips operates a broad medical imaging portfolio including nuclear medicine systems. It is a broad incumbent whose installed base represents both a distribution opportunity and a potential competitive threat for adjunct nuclear-medicine QA tools.

2CIRS (Computerized Imaging Reference Systems)
TypeEmerging player
Description

CIRS develops tissue-mimicking phantoms and QA tools used across diagnostic imaging modalities including nuclear medicine. It is an emerging player that serves the same hospital medical-physics QA buyer as Lucerno.

TypeEmerging player
Description

LabLogic provides instrumentation and software for radiochromatography, PET radiopharmaceutical QC, and radiation detection. Its PET-specific QC product line targets the same nuclear-medicine radiochemistry QA workflow where Lucerno's injection-quality monitoring operates.

TypeBroad incumbent
Description

Siemens Healthineers is a global leader in molecular imaging (PET/CT, SPECT) and is also Lucerno's master reseller. As a broad incumbent, it could over time develop or acquire competing radiopharmaceutical-injection monitoring capability, creating channel conflict risk.

5Biodex Medical Systems
TypeDirect peer
Description

Biodex supplies nuclear medicine equipment including thyroid uptake systems and surgical C-arms, with deep hospital nuclear medicine department relationships. It competes for the same nuclear-medicine QA capital budgets that fund Lara System adoption.

TypeBroad incumbent
Description

GE HealthCare is a dominant medical imaging OEM with a large nuclear medicine / PET installed base and a broad portfolio of nuclear medicine QC accessories. It is a broad incumbent that could embed competing injection-monitoring capabilities into its imaging consoles.

TypeBroad incumbent
Description

Mirion is a broad incumbent in radiation detection and monitoring across nuclear power, medical, and defense markets. Following its acquisition of Capintec and ownership of Sun Nuclear, Mirion has the scale and channel to bundle a competing extravasation-monitor capability into its existing nuclear-medicine QA portfolio.

TypeDirect peer
Description

Sun Nuclear provides quality assurance instrumentation for radiation therapy and diagnostic imaging, including patient-specific QA tools. Its positioning around radiation-procedure quality assurance overlaps directly with Lucerno's extravasation-monitoring and QA reporting value proposition.

TypeDirect peer
Description

Capintec manufactures radiation detection and measurement instruments for nuclear medicine, including dose calibrators and well counters used to verify radiopharmaceutical activity. Like Lucerno, its products sit at the QA/QC intersection of radiopharmaceutical handling and clinical nuclear medicine workflow, making it the closest functional peer.

TypeBroad incumbent
Description

Bruker is a broad incumbent in analytical and preclinical imaging instrumentation with PET and nuclear-medicine-adjacent product lines. Its scale in radiation-detection and imaging platforms makes it a relevant adjacent incumbent for valuation benchmarking.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lucerno Dynamics

Nuclear Medicine Medical Deviceslucerno.com

Lucerno Dynamics is a Cary, NC medical device company that developed the Lara System, passive skin sensors with companion Ellexa software that detect radiopharmaceutical extravasations in real time during nuclear medicine procedures for hospital and academic imaging departments.

What Lucerno Dynamics does

Lucerno Dynamics, LLC is a Cary, North Carolina-based medical device company founded in November 2011 that develops the Lara System, a passive surface-sensor platform used during nuclear medicine procedures to detect radiopharmaceutical extravasations — the inadvertent leakage of injected radioactive tracers into surrounding tissue rather than the intended vein. The Lara System applies topical sensors to the patient's skin to detect radiation during the entire uptake period without emitting energy itself, producing real-time time-activity curves (TACs) that can be stored in PACS as part of the patient record. The companion Ellexa Explorer software scores bolus injections, displays histograms, runs advanced analytics, and generates monthly QA reports; Lara Real-Time Visualization (RTV) extends the platform with second-by-second graphical feedback and statistical control charts for therapeutic radiopharmaceutical administrations. Lucerno has also built a deep learning classifier that labels TAC data to identify extravasated injections.

The company monetizes through hardware sales of the Lara System (sensors, adhesive pads, monitoring equipment) bundled with Ellexa software, sold via direct enterprise field sales to hospital and academic nuclear medicine departments and via channel partners — most notably a Master Reseller Agreement with Siemens Healthineers (signed July 2021) covering US distribution, supplemented by a global partners network spanning Australia, Singapore, Japan, and Europe. Pricing is proposal-based and undisclosed, with multi-year contracts typical of medical imaging capital purchases. Key accounts include Carilion Clinic, Mayo Clinic, Saint Louis University, Wake Forest Baptist Hospital, and University of Pennsylvania, with the technology clinically validated across nearly 50,000 administrations.

The company's strategic posture has combined clinical evidence generation (the multi-center Lara-QI study), regulatory advocacy (a successful 2022 NRC petition for rulemaking to close the extravasation reporting exemption), and channel-led commercialization. After raising $6.34M in Series A equity in 2016 and several smaller debt and equity tranches through 2023, the company remained sub-scale at 1–10 employees, and in July 2026 sold its core Lara and Ellexa assets to Radnostix, Inc., signaling a transition out of independent operations.

Lucerno Dynamics firmographics

Firmographics
Name
Lucerno Dynamics
Legal name
Lucerno Dynamics, LLC
Website
https://lucerno.com
Company type
Private
Founded year
2011
Operating status
Acquired
Headcount range
1–10 employees
Short description
Lucerno Dynamics is a Cary, NC medical device company that developed the Lara System, passive skin sensors with companion Ellexa software that detect radiopharmaceutical extravasations in real time during nuclear medicine procedures for hospital and academic imaging departments.
Ownership category
akta.pro rank

Lucerno Dynamics industry classification

Industry
Product category
Nuclear Medicine Medical Devices
NAICS
Analytical Laboratory Instrument Manufacturing (334516)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHABAI
Imaging Informatics & Workflow (PACS/RIS/VNA)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLACALAL
Quality, Peer Review & Compliance Tools (MQSA/ACR/QA)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACALAK
Teleradiology Platforms & Reading Workflow
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT

Keywords

  • Radiopharmaceutical extravasation monitoring
  • Nuclear medicine injection quality
  • Medical radiation sensors
  • PET/CT quality assurance
  • Radiotherapy administration monitoring

Where Lucerno Dynamics is headquartered

Location

Headquarters

HQ city
Cary
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Lucerno Dynamics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Medical Device Sales - Lara System: Sale of the Lara System hardware including sensors, adhesive pads, and associated monitoring equipment for nuclear medicine facilities.
  2. Software - Ellexa Explorer: PC application software for data analysis, quality assurance reporting, and advanced analytics. Provided as part of the Lara System offering.
  3. Therapy Response Monitoring (Investigational): Investigational technology for therapy response monitoring in solid tumor treatment, used under investigational device exemption. Not yet cleared or approved by FDA for this indication.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractLara System for nuclear medicine injection monitoring

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Lucerno Dynamics product offering

Product offering

Core offering

Lucerno Dynamics develops and sells the Lara System, a medical device platform that uses topical surface sensors to dynamically detect and measure radiopharmaceutical extravasations during nuclear medicine procedures. The system provides real-time quality control data, time-activity curve analysis, and quality assurance software (Ellexa Explorer) for hospital nuclear medicine departments performing PET/CT scans and therapeutic radiopharmaceutical administrations.

Product overview

Lucerno Dynamics offers a unified product ecosystem centered on the Lara System platform for detecting and monitoring radiopharmaceutical extravasations during nuclear medicine procedures. The core Lara System uses passive surface sensors to provide real-time quality control data. Key software modules include Ellexa Explorer (for data analysis, automated scoring, and reporting) and Lara Real-Time Visualization (for therapeutic monitoring with statistical control charts). These components work together to help clinicians identify injection errors within seconds, evaluate their impact through time-activity curves, and reduce extravasation frequency through quality assurance programs.

Differentiator

Problem solved

Functional benefit

Brands

  • LARA System: FDA-listed system that dynamically measures the presence of radiopharmaceutical in an organ or body region during uptake period; provides quality control, dosimetry, and quality assurance for nuclear medicine administrations
  • ELLEXA Explorer
  • LARA Real-Time Visualization (RTV)

Products and services

  • Lara System The Lara System is the primary product platform using passive surface sensors applied to a patient's skin to detect radiation emitted from areas of interest during and after radiopharmaceutical administration. It provides real-time quality control data for detecting extravasations in nuclear medicine procedures such as PET/CT scans and radiotherapeutic administrations. Targeted at hospital nuclear medicine departments, cancer centers, and imaging facilities.
  • Lara Real-Time Visualization (RTV) Lara RTV provides second-by-second graphical time-activity curve feedback on a computer monitor during therapeutic radiopharmaceutical administrations. Includes statistical control charts that alert technologists when administrations may have been extravasated, enabling early intervention to minimize accidental radiation exposures. Targeted at nuclear medicine technologists performing radiotherapeutic administrations.
  • Ellexa Explorer Software Ellexa Explorer is a PC application that automatically scores bolus injections, displays histograms of injection scores, provides advanced analytics to identify factors leading to injection issues, and generates monthly reports for departments and individual technologists. Targeted at nuclear medicine department quality managers and QA personnel.

Quantifiable outcome

  • Extravasation rates reduced to 2-16% when centers implement quality improvement programs with Lara System
  • +3 more outcomes

Companies that use Lucerno Dynamics

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Lucerno Dynamics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature4 records

Lucerno Dynamics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • RadnostixcoreOthers · 2 July 2026Radnostix acquired key assets from Lucerno Dynamics including the LARA System technology platform, ELLEXA Explorer software, and associated intellectual property for radiopharmaceutical and nuclear medicine applications. Note: This represents an asset acquisition of Lucerno's technology portfolio.
  • Siemens HealthineerscoreChannel Partner/ Reseller/ Distributor · 8 July 2021Master Resellers Agreement making the Lara System part of Siemens Healthineers' portfolio of medical imaging products. Siemens Healthineers became Lucerno's first United States partner reseller, making Lara System available to nuclear medicine customers nationwide.
  • CRD AssociatescoreStrategic or Co-development PartnerWashington, D.C. partners supporting Lucerno's public policy efforts to improve patient safety and nuclear medicine procedure quality through regulatory engagement.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Lucerno Dynamics competitors and assessment

Company assessment

Broad incumbents

  • Philips: Philips operates a broad medical imaging portfolio including nuclear medicine systems. It is a broad incumbent whose installed base represents both a distribution opportunity and a potential competitive threat for adjunct nuclear-medicine QA tools.
  • Siemens Healthineers: Siemens Healthineers is a global leader in molecular imaging (PET/CT, SPECT) and is also Lucerno's master reseller. As a broad incumbent, it could over time develop or acquire competing radiopharmaceutical-injection monitoring capability, creating channel conflict risk.
  • GE HealthCare: GE HealthCare is a dominant medical imaging OEM with a large nuclear medicine / PET installed base and a broad portfolio of nuclear medicine QC accessories. It is a broad incumbent that could embed competing injection-monitoring capabilities into its imaging consoles.
  • Mirion Technologies: Mirion is a broad incumbent in radiation detection and monitoring across nuclear power, medical, and defense markets. Following its acquisition of Capintec and ownership of Sun Nuclear, Mirion has the scale and channel to bundle a competing extravasation-monitor capability into its existing nuclear-medicine QA portfolio.
  • Bruker: Bruker is a broad incumbent in analytical and preclinical imaging instrumentation with PET and nuclear-medicine-adjacent product lines. Its scale in radiation-detection and imaging platforms makes it a relevant adjacent incumbent for valuation benchmarking.

Emerging players

  • CIRS (Computerized Imaging Reference Systems): CIRS develops tissue-mimicking phantoms and QA tools used across diagnostic imaging modalities including nuclear medicine. It is an emerging player that serves the same hospital medical-physics QA buyer as Lucerno.
  • LabLogic Systems: LabLogic provides instrumentation and software for radiochromatography, PET radiopharmaceutical QC, and radiation detection. Its PET-specific QC product line targets the same nuclear-medicine radiochemistry QA workflow where Lucerno's injection-quality monitoring operates.

Direct peers

  • Biodex Medical Systems: Biodex supplies nuclear medicine equipment including thyroid uptake systems and surgical C-arms, with deep hospital nuclear medicine department relationships. It competes for the same nuclear-medicine QA capital budgets that fund Lara System adoption.
  • Sun Nuclear (a Mirion brand): Sun Nuclear provides quality assurance instrumentation for radiation therapy and diagnostic imaging, including patient-specific QA tools. Its positioning around radiation-procedure quality assurance overlaps directly with Lucerno's extravasation-monitoring and QA reporting value proposition.
  • Capintec (Mirion Technologies): Capintec manufactures radiation detection and measurement instruments for nuclear medicine, including dose calibrators and well counters used to verify radiopharmaceutical activity. Like Lucerno, its products sit at the QA/QC intersection of radiopharmaceutical handling and clinical nuclear medicine workflow, making it the closest functional peer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Lucerno Dynamics social profiles

Digital presence

Lucerno Dynamics compliance and trust

Trust signal

Compliance3 records

Lucerno Dynamics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lucerno Dynamics leadership team

Management profile

Number of profiles

Profiles5 records

Lucerno Dynamics funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lucerno Dynamics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lucerno Dynamics

What does Lucerno Dynamics do?

Lucerno Dynamics develops and sells the Lara System, a medical device platform that uses topical surface sensors to dynamically detect and measure radiopharmaceutical extravasations during nuclear medicine procedures. The system provides real-time quality control data, time-activity curve analysis, and quality assurance software (Ellexa Explorer) for hospital nuclear medicine departments performing PET/CT scans and therapeutic radiopharmaceutical administrations.

Is Lucerno Dynamics a public or private company?

Lucerno Dynamics is a private company. It is classified as venture growth investor backed and is currently acquired.

When was Lucerno Dynamics founded?

Lucerno Dynamics was founded in 2011. It employs 1 to 10 people.

Where is Lucerno Dynamics based?

Lucerno Dynamics is headquartered in Cary, United States, in the North America region.

How does Lucerno Dynamics make money?

Three revenue lines are on record. Medical Device Sales - Lara System is the primary driver. The others are software - Ellexa Explorer and therapy Response Monitoring (Investigational).

Who are Lucerno Dynamics's main competitors?

Broad incumbents on record are Philips, Siemens Healthineers, GE HealthCare, Mirion Technologies and Bruker. Emerging players are CIRS (Computerized Imaging Reference Systems) and LabLogic Systems. Direct peers are Biodex Medical Systems, Sun Nuclear (a Mirion brand) and Capintec (Mirion Technologies).

Does Lucerno Dynamics have an API?

No public API is recorded for Lucerno Dynamics.

What industry is Lucerno Dynamics in?

Lucerno Dynamics's product category is Nuclear Medicine Medical Devices. Its primary akta.pro industry code is HLAHABAI, Imaging Informatics & Workflow (PACS/RIS/VNA), with a secondary code of HLACALAL, Quality, Peer Review & Compliance Tools (MQSA/ACR/QA). Its NAICS code is 334516 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AInvestRadnostix, Inc. reports FY2026 2nd quarter and six months results - completes execution of FDA 483 & recall actions, restores capsule inventory, completes Lucerno Dynamics asset acquisitionRadnostix, Inc. reported a 27% decline in second-quarter revenue to $2.67 million due to voluntary product recalls and a temporary shutdown of its Cobalt Products facility, resulting in a net loss of $0.88 million. The company completed FDA corrective actions for Form 483 observations, restored capsule inventory, and acquired the assets of Lucerno Dynamics to expand its medical devices portfolio.PR NewswireRadnostix, Inc. Reports FY2026 2nd Quarter and Six Months Results - Completes Execution of FDA 483 & Recall Actions, Restores Capsule Inventory, Completes Lucerno Dynamics Asset AcquisitionRadnostix, Inc. reported a 27% decline in second-quarter revenue to $2.67 million and widened its net loss to $0.88 million for the period ended June 30, 2026, primarily due to voluntary product recalls and a Cobalt Products shutdown. The company has completed FDA remediation actions, fully restored capsule inventory, and acquired Lucerno Dynamics' assets to expand its medical devices portfolio.Pulse 2.0Radnostix Acquires Lucerno Dynamics AssetsRadnostix announced the acquisition of key assets from Lucerno Dynamics, including the LARA System technology platform, ELLEXA Explorer software, and associated intellectual property for radiopharmaceutical and nuclear medicine applications. The acquired technology helps identify and reduce extravasations during IV-administered radiopharmaceuticals and includes real-time visualization features for theranostics administration. The company expects the acquisition to support development of drug uptake monitoring, dosimetry systems, and potential pairing with drug injection systems as it expands into a broader solutions provider role in the theranostics market.BiospectrumjobsRadnostix Acquires Lucerno Dynamics Assets Expanding Radiopharma Medical Device PortfolioRadnostix closed its acquisition of key assets from Lucerno Dynamics, including the LARA System and ELLEXA software. The LARA System has been clinically proven in nearly 50,000 administrations across multiple countries. The acquisition aims to expand Radnostix's radiopharmaceutical and nuclear medicine device portfolio.citybizRadnostix Acquires Lucerno Dynamics Assets to Expand Nuclear Medicine Device PortfolioRadnostix has acquired key assets from Lucerno Dynamics, including the LARA® System, ELLEXA® Explorer software and related intellectual property, to expand its portfolio in radiopharmaceutical delivery and nuclear medicine applications. The acquisition adds technologies designed to improve administration and monitoring of radiopharmaceutical therapies, including real-time visualization capabilities for detecting intravenous extravasations during treatment. Radnostix plans to use the acquired technology to develop additional products that simplify radiopharmaceutical delivery while improving clinical safety and operational efficiency, positioning itself as a comprehensive solutions provider in the theranostics market.GurufocusRadnostix Acquires Lucerno Dynamics Assets Expanding RadiopharmaRadnostix, Inc. has completed the acquisition of key assets from Lucerno Dynamics, LLC, including the LARA® System technology platform, ELLEXA® Explorer software, and associated intellectual property for radiopharmaceutical administration. The acquisition enables Radnostix to expand into patient safety and dosimetry applications in the rapidly growing theranostics market, with products that can monitor drug uptake and reduce extravasations during nuclear medicine procedures. The LARA System has been clinically proven in nearly 50,000 administrations across major international markets including Australia, Singapore, Japan, Europe, and the United States.PR NewswireRadnostix Acquires Lucerno Dynamics Assets Expanding Radiopharma Medical Device PortfolioRadnostix, Inc. announced the successful closing of its acquisition of key assets from Lucerno Dynamics, LLC, including the LARA® System technology platform, ELLEXA® Explorer software, and associated intellectual property. The acquired technology helps identify and reduce extravasations of IV administered radiopharmaceuticals and has been clinically proven in nearly 50,000 administrations. This strategic acquisition enables Radnostix to expand its portfolio in the theranostics delivery and administration market, positioning the company as a comprehensive solutions provider for radiopharmaceutical and nuclear medicine applications.TradingViewRadnostix Acquires Lucerno Dynamics Assets Expanding Radiopharma Medical Device PortfolioRadnostix, Inc. announced the successful closing of its acquisition of key assets from Lucerno Dynamics, LLC, including the LARA System technology platform and associated intellectual property for radiopharmaceutical dosimetry. This strategic move allows Radnostix to expand its portfolio into new product offerings aimed at improving safety and efficiency in nuclear medicine applications. The acquired technologies have been clinically proven in nearly 50,000 administrations across multiple countries.AuntMinnieControversy clouds nuclear medicine bill in CongressThe Nuclear Medicine Clarification Act of 2025 (H.R. 2541) was reintroduced in the House to mandate the reporting of diagnostic radiopharmaceutical extravasations as medical mistakes, overriding current exemptions. Radiology societies including SNMMI and ACR oppose the bill, arguing it serves the interests of petitioner Lucerno Dynamics rather than patient safety, while proponents claim it closes a transparency loophole.